Protara Historical Income Statement
| TARA Stock | USD 2.94 0.34 13.08% |
Historical analysis of Protara Therapeutics income statement accounts such as Other Operating Expenses of 32.4 M, Preferred Stock And Other Adjustments of 7.2 M, Research Development of 17.2 M or Total Operating Expenses of 32.4 M can show how well Protara Therapeutics performed in making a profits. Evaluating Protara Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Protara Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Protara Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Protara Therapeutics is a good buy for the upcoming year.
Protara |
About Protara Income Statement Analysis
Protara Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Protara Therapeutics shareholders. The income statement also shows Protara investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Protara Therapeutics Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Protara Therapeutics. It is also known as Protara Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Protara Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Protara Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Protara Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Protara Stock refer to our How to Trade Protara Stock guide.At present, Protara Therapeutics' Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Total Other Income Expense Net is expected to grow to about 3.4 M, whereas Depreciation And Amortization is forecasted to decline to about 268.5 K.
| 2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 117K | 248K | 309K | 231.7K | Interest Income | 2.0M | 2.2M | 3.0M | 3.1M |
Protara Therapeutics income statement Correlations
Click cells to compare fundamentals
Protara Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Protara Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 17K | 196K | 1.2M | 247K | 341K | 268.5K | |
| Selling General Administrative | 8.8M | 22.5M | 26.4M | 20.7M | 18.6M | 15.3M | |
| Other Operating Expenses | 15.3M | 34.4M | 47.5M | 37.5M | 43.6M | 32.4M | |
| Operating Income | (15.3M) | (34.4M) | (47.5M) | (67.1M) | (43.6M) | (45.8M) | |
| Net Income From Continuing Ops | (15.0M) | (34.0M) | (47.3M) | (66.0M) | (69.2M) | (65.7M) | |
| Ebit | (15.3M) | (34.0M) | (47.3M) | (64.8M) | (43.6M) | (45.8M) | |
| Research Development | 6.4M | 12.0M | 21.1M | 16.8M | 25.0M | 17.2M | |
| Ebitda | (15.2M) | (33.8M) | (46.1M) | (64.6M) | (43.3M) | (45.4M) | |
| Total Operating Expenses | 15.3M | 34.4M | 47.5M | 37.5M | 43.6M | 32.4M | |
| Income Before Tax | (15.0M) | (34.0M) | (47.3M) | (66.0M) | (40.4M) | (42.4M) | |
| Total Other Income Expense Net | 262K | 466K | 237K | 1.1M | 3.2M | 3.4M | |
| Net Income Applicable To Common Shares | (15.0M) | (34.0M) | (47.3M) | (66.0M) | (59.4M) | (56.4M) | |
| Net Income | (14.7M) | (33.5M) | (47.1M) | (64.8M) | (40.4M) | (42.4M) | |
| Income Tax Expense | (262K) | (466K) | (117K) | (1.1M) | (341K) | (324.0K) | |
| Interest Income | 262K | 500K | 2.0M | 2.2M | 3.0M | 3.1M | |
| Reconciled Depreciation | 279K | 196K | 117K | 248K | 309K | 231.7K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Protara Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Protara Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Protara Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Protara Therapeutics Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Protara Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Protara Stock refer to our How to Trade Protara Stock guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protara Therapeutics. If investors know Protara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protara Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.64) | Return On Assets (0.28) | Return On Equity (0.46) |
The market value of Protara Therapeutics is measured differently than its book value, which is the value of Protara that is recorded on the company's balance sheet. Investors also form their own opinion of Protara Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protara Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protara Therapeutics' market value can be influenced by many factors that don't directly affect Protara Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protara Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protara Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protara Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.